From: IMRT and carbon ion boost for malignant salivary gland tumors: interim analysis of the COSMIC trial
R2: visible residual tumor | R1: R1/ Pn + resected tumors | ||||
---|---|---|---|---|---|
end of RT | 1st f/u | end of RT | 1st f/u | ||
Mucositis | I | 3 (18.8%) | 1 (6.3%) | 4 (30.8%) | 0 |
II | 7 (43.8%) | 0 | 6 (46.2%) | 0 | |
III | 4 (25%) | 0 | 2 (15.4%) | 0 | |
Dermatitis | I | 13 (81.3%) | 0 | 12 (92.3%) | 1 (7.7%) |
II | 2 (12.5%) | 0 | 0 | 0 | |
III | 1 (6.3%) | 0 | 1 (7.7%) | 0 | |
Xerostomia | I | 7 (43.8%) | 10 (62.5%) | 6 (46.2%) | 11 (84.6%) |
II | 0 | 2 (12.5%) | 2 (15.4%) | 0 | |
Dysphagia | I | 7 (43.8%) | 2 (12.5%) | 4 (30.8%) | 0 |
II | 0 | 0 | 2 (15.4%) | 0 | |
III | 0 | 0 | 0 | 0 | |
Weight loss | yes | 13 (81.3%) | 3 (18.8%) | 9 (69.2%) | 4 (30.8%) |
kg | median | 5 | 5,5 | ||
min | 3 | 5 | |||
max | 10 | 12 | |||
Feeding tube | 0 | 0 | 0 | 0 | |
Loss of taste | 16 (100%) | 0 | 11 (84.6%) | 0 | |
Middle ear effusion | 6 (37.5%) | 5 (31.3%) | 2 (15.4%) | 2 (15.4%) | |
Otitis | 0 | 0 | 0 | 0 | |
Paralysis of facial nerve | 1 (6.3%) | 1 (6.3%) | 1 (7.7%) | 1 (7.7%) | |
Ptosis | 1 (6.3%) | 1 (6.3%) | 0 | 0 | |
Reduced jaw opening | 2 (12.5%) | 2 (12.5%) | 1 (7.7%) | 1 (7.7%) | |
Xerophthalmia | 0 | 1 (6.3%) | 1 (7.7%) | 0 | |
Conjunctivitis | 1 (6.3%) | 0 | 0 | 0 | |
Lymph edema | 1 (6.3%) | 1 (6.3%) | 0 | 2 (15.4%) | |
Hearing impairment | 2 (12.5%) | 0 | 0 | 0 |